RxPG News Feed for RxPG News

Medical Research Health Special Topics World
  Home
 
   Health
 Aging
 Asian Health
 Events
 Fitness
 Food & Nutrition
 Happiness
 Men's Health
 Mental Health
 Occupational Health
 Parenting
 Public Health
 Sleep Hygiene
 Women's Health
 
   Healthcare
 Africa
 Australia
 Canada Healthcare
 China Healthcare
 India Healthcare
 New Zealand
 South Africa
 UK
 USA
 World Healthcare
 
   Latest Research
 Aging
 Alternative Medicine
 Anaethesia
 Biochemistry
 Biotechnology
 Cancer
  Bladder
  Blood
  Bone Cancer
  Brain
  Breast Cancer
  Carcinogens
  Cervical Cancer
  Colon
  Endometrial
  Esophageal
  Gastric Cancer
  Liver Cancer
  Lung
  Nerve Tissue
  Ovarian Cancer
  Pancreatic Cancer
  Prostate Cancer
  Rectal Cancer
  Renal Cell Carcinoma
  Risk Factors
  Skin
  Testicular Cancer
  Therapy
  Thyroid
 Cardiology
 Clinical Trials
 Cytology
 Dental
 Dermatology
 Embryology
 Endocrinology
 ENT
 Environment
 Epidemiology
 Gastroenterology
 Genetics
 Gynaecology
 Haematology
 Immunology
 Infectious Diseases
 Medicine
 Metabolism
 Microbiology
 Musculoskeletal
 Nephrology
 Neurosciences
 Obstetrics
 Ophthalmology
 Orthopedics
 Paediatrics
 Pathology
 Pharmacology
 Physiology
 Physiotherapy
 Psychiatry
 Radiology
 Rheumatology
 Sports Medicine
 Surgery
 Toxicology
 Urology
 
   Medical News
 Awards & Prizes
 Epidemics
 Launch
 Opinion
 Professionals
 
   Special Topics
 Ethics
 Euthanasia
 Evolution
 Feature
 Odd Medical News
 Climate

Last Updated: Oct 11, 2012 - 10:22:56 PM
Cervical Cancer Channel

subscribe to Cervical Cancer newsletter
Latest Research : Cancer : Cervical Cancer

   EMAIL   |   PRINT
Vaccine for Cervical Cancer Approved in US - Overview

Jun 9, 2006 - 2:05:00 AM , Reviewed by: Priya Saxena
Recombinant vaccines are made by genetic engineering, the process and method of manipulating the genetic material of an organism. In this case, the genes that code for a specific protein from each of the four virus types of HPV are expressed in yeast to create large quantities of the protein.

 
[RxPG] FDA has now announced the licensure of Gardasil, the first vaccine for the prevention of cervical cancer, abnormal and precancerous cervical lesions, abnormal and precancerous vaginal and vulvar lesions and genital warts. Gardasil is a recombinant vaccine and is effective against HPV types 6, 11, 16 and 18, and is approved for use in females ages 9-26 years.

Recombinant vaccines are made by genetic engineering, the process and method of manipulating the genetic material of an organism. In this case, the genes that code for a specific protein from each of the four virus types of HPV are expressed in yeast to create large quantities of the protein. The protein that is produced is purified and then used to make the vaccine. Because the vaccine only contains a protein, and not the entire virus, the vaccine cannot cause the HPV infection. It is the body's immune response to the recombinant protein(s) that then protects against infection by the naturally occurring virus.

HPV is the name of a group of viruses that includes more than 100 different types. More than 30 of these viruses can be passed from one person to another through sexual contact. For most women, the body's own defense system will clear the virus and they don't develop health problems. However, some types can cause cervical cancer or abnormal cells in the lining of the cervix that can sometimes progress to cancer. Other types are a major cause of genital warts.

For women who do develop cervical cancer, HPV is generally the root cause. In 2006, it is estimated that there will be 9,710 new cases of cervical cancer and 3,700 deaths attributed to it in the United States. Worldwide, cervical cancer is the second most common cancer in women; and it is estimated to cause over 470,000 new cases and 233,000 deaths per year.

HPV is the most common sexually transmitted infection in the United States. The Centers for Disease Control and Prevention (CDC) estimates that about 6.2 million Americans become infected with genital HPV each year and that over half of all sexually active men and women become infected at some time in their lives.

The vaccine is effective against HPV types 16 and 18 which cause approximately 70% of cervical cancers, and against HPV types 6 and 11 which cause approximately 90% of genital warts.

Gardasil is expected to prevent up to 70% of cervical cancers, because they are due to HPV types against which the vaccine is directed. However, it does not protect against the types of HPV that are not included in the vaccine, which can also cause some cancers. Furthermore, women aren't protected if they have already been infected with the HPV types(s) that are covered by the vaccine prior to vaccination.

Since no vaccine is 100% effective and Gardasil won't provide protection against the HPV types not in the vaccine, or against existing HPV infections, routine Pap screening remains critically important to detect precancerous changes in the cervix to allow treatment before cervical cancer develops.

Four multinational studies were conducted to show how well Gardasil worked in women between the ages of 16 and 26 by giving them either the vaccine or placebo. The results showed that in women who had not already been infected with the type of HPV contained in the vaccine, Gardasil was nearly 100 percent effective in preventing precancerous cervical lesions, precancerous vaginal and vulvar lesions and genital warts caused by infection with the HPV types against which the vaccine is directed . It is believed that prevention of cervical precancerous lesions is highly likely to result in the prevention of those cancers.

Two studies were also performed to measure the immune response to the vaccine among younger females aged 9-15 years. Their immune response was similar to that found in 16-26 year olds, indicating that the vaccine should have similar effectiveness when used in the 9-15 year age group.

It is important to note that Gardasil did not protect against HPV types that are not in the vaccine.

Gardasil only works to prevent cervical cancer, precancerous genital lesions and genital warts due to human papillomavirus (HPV); it won't work as treatment.

In the studies, females with current or past infection with one or more vaccine-related HPV types prior to vaccination were protected from the diseases caused by the other remaining HPV types contained in the vaccine.

Gardasil is not approved for use in males, but the manufacturer currently has a study underway to see if it is safe and effective for them. Once the study is complete and submitted to FDA, the agency will review the data and decide whether to approve Gardasil for males.

Gardasil is given as three injections over a six-month period; the first dose is given at an initial time selected by the vaccine recipient and her healthcare practitioner, followed by another dose 2 months later, and the third and last dose, six months after the first dose. The vaccine is administered intramuscularly in the upper arm or thigh.

The results of the studies show that the vaccine only works when given prior to infection with HPV types 6, 11, 16 and 18.

FDA has approved Gardasil as safe and effective for use in females ages 9-26 years. Now that the vaccine has been licensed, CDC's Advisory Committee on Immunization Practices (ACIP) will discuss Gardasil at its June 29, 2006, meeting and make recommendations concerning its use.

More than 10,500 females who received Gardasil were evaluated for adverse reactions. Most of the reactions experienced by the study participants were not serious and included mild or moderate local reactions, such as pain or tenderness at the site of the injection. It is always possible that unexpected and rare adverse events can occur when a vaccine is used more widely. The manufacturer has committed to FDA to performing additional studies of the safety of Gardasil. In addition, FDA and CDC carefully monitor the safety of approved vaccine through the Vaccine Adverse Event Reporting System (VAERS) in order to detect any problems.

Females who are allergic to yeast or to any component of the vaccine should not receive Gardasil. FDA has approved Gardasil as safe and effective for use in females ages 9-26 years.

Gardasil is not a live virus vaccine; it does not contain the HPV virus and therefore, cannot cause the HPV infection. Gardasil does not contain thimerosal or any other preservative.



Publication: Food and Drug Administration (FDA), USA
On the web: www.fda.gov 

Advertise in this space for $10 per month. Contact us today.


Related Cervical Cancer News
New vaccine prevents cervical cancer in teens
Topotecan for Late-Stage Cervical Cancer Approved
New HPV vaccine is 100 percent effective
Vaccine for Cervical Cancer Approved in US - Overview
Quadrivalent Human Papillomavirus (HPV) Recombinant Vaccine Approved by FDA
HPV Vaccination: Predicting Its Effect on Cervical Cancer Rates
HPV testing is more sensitive for screening cervical cancer
Community's income status predicts cervical screening rates
Novel technique to remove "inoperable" cervical spinal tumours
HPV Vaccine Prevented 100 Percent of Cervical Pre-cancers

Subscribe to Cervical Cancer Newsletter

Enter your email address:


 Additional information about the news article
Adverse reactions and other problems related to vaccines should be reported to the Vaccine Adverse Event Reporting System, which is maintained by FDA and CDC. For a copy of the vaccine reporting form, call 1-800-822-7697 or report on line to www.vaers.hhs.gov.

This overview is an abridged version of FDA questions and answers on Gardasil
 Feedback
For any corrections of factual information, to contact the editors or to send any medical news or health news press releases, use feedback form

Top of Page

 
Contact us

RxPG Online

Nerve

 

    Full Text RSS

© All rights reserved by RxPG Medical Solutions Private Limited (India)